Upstream / Downstream
Explore pathways related to this product.
Our U.S. Offices Will Be Closing Early
Our U.S. offices will be closing early on November 26th at 6:00 PM EST.
Find answers on our FAQs page.
PTM information and tools available.
Phospho-HER2/ErbB2 (Tyr1112) Antibody #2245
This product is discontinued
Gallery: Phospho-HER2/ErbB2 (Tyr1112) Antibody #2245
Phospho-HER2/ErbB2 (Tyr1112) Antibody detects ErbB2 only when activated by phosphorylation at Tyr1112. This antibody may cross-react with other activated ErbB family members (e.g. EGF receptor).
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding tyrosine 1112 of human ErbB2. Antibodies are purified by protein A and peptide affinity chromatography.
The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.